the AUC values between 5 and 7 hr were significantly decreased by ER-319711-15 and vildagliptin, but not by E3024. Therefore, ER-319711 might be a potent, competitive and selective DPP-IV inhibitor with an antihyperglycemic activity.
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Introduction
Dipeptidyl peptidase (DPP)-IV degrades active glucagon-like peptide-1 (GLP-1 (7-36)amide and GLP-1(7-37)), which is an incretin released from L cells in the intestine after meal intake that enhances insulin secretion in a glucose-dependent manner. GLP-1 has an antidiabetic action in patients with type 2 diabetes (Gutniak et al., 1994; Nauck et al., 1993) . DPP-IV cleaves GLP-1 rapidly so the latter's half-life is only 1-2 min. Accordingly, the prevention of GLP-1 inactivation by DPP-IV inhibition is currently being actively explored as a novel approach to the treatment of type 2 diabetes (Deacon et al., 2004) . DPP-IV inhibition leads to blood glucose-lowering effects in animal models of diabetes (Pederson et al., 1998; Reimer et al., 2002; Burkey et al, 2005) , and in patients with type 2 diabetes .
7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one (ER-319711) is a novel DPP-IV inhibitor discovered in our laboratories. Demuth et al. (2005) categorized DPP-IV inhibitors based on their mode of inhibition and structures as follows: reversible product analog inhibitors (e.g. P32/98 (Sorbera, et al., 2001 )), covalently modifying product analog inhibitors (e.g. vildagliptin (LAF237) (Villhauer et al., 2003) ), and reversible non-peptidic heterocyclic inhibitors (e.g. sitagliptin (MK-0431) ). ER-319711 belongs to the third group, and is a novel, 8-oxo-purine derivative.
In this study, we have characterized the inhibition mode for DPP-IV and enzyme selectivity towards DPP-IV, DPP8 and DPP9 of the newly discovered DPP-IV inhibitor, and investigated its antihyperglycemic activity using Zucker fa/fa rats and mice fed a high-fat diet. The high-fat diet-fed mouse model considered to be a robust model for impaired glucose tolerance and early type 2 diabetes (Winzell and Ahrén, 2004) , both of which are targets of DPP-IV inhibitors.
This article has not been copyedited and formatted. The final version may differ from this version. pyrrolidide) was purchased from Bachem AG (Bubendorf, Switzerland), which is a non-selective DPP-IV/DPP8/DPP9 inhibitor ( (Lankas et al., 2005) , used as a reference.
The chemical structures of these compounds are shown in Figure 1 . Committee's guideline.
Inhibitory effects towards DPP-IV
Plasma insulin and active GLP-1 levels in an oral glucose tolerance test (OGTT) using Zucker fa/fa rats. ER-319711-15 (1 mg/kg) or vehicle (0.5% methyl cellulose (MC)) was orally administered to overnight-fasted Zucker fa/fa rats 0.5 hr prior to oral glucose load (2 g/kg). Blood samples were drawn from the tail vein -0.5, 0, 0.5, 1, 2 and JPET #112805
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OGTT using mice fed a high-fat diet: dose-dependency of efficacy of ER-319711-15.
Mice were fed a high-fat diet (D12492 Rodent Diet with 60 kcal% fat) for four weeks from 11 weeks of age, and 42 mice were selected based on absolute body weight and randomly divided into seven groups. ER-319711-15 (0.1, 0.3, 1, 3 and 10 mg/kg), vildagliptin (10 mg/kg) as a positive control, or vehicle (0.5% MC) alone was orally administered to overnight-fasted mice at the same time of oral glucose administration (2 g/kg) (0 hr). After five hours, glucose was orally administered again. Blood samples were collected from the tail vein 0, 0.5, 1, 2, 5, 5.5, 6 and 7 hr after the compound treatment.
OGTT using mice fed a high-fat diet: comparison of efficacy between E3024, ER-319711-15 and vildagliptin. Mice were fed a high-fat diet (D12492 Rodent Diet with 60 kcal% fat; Research Diets, Inc., NJ) for four weeks from 11 weeks of age, and 24 mice were selected based on body weight and randomly divided into four groups.
E3024 (10 mg/kg), ER-319711-15 (10 mg/kg), vildagliptin (10 mg/kg), or vehicle (0.5% MC) alone was orally administered to overnight-fasted mice at the same time of oral glucose administration (2 g/kg) (0 hr). After five hours, glucose was orally administered again. Blood samples were collected from the tail vein 0, 0.5, 1, 2, 5, 5.5, 6 and 7 hr after the compound treatment.
Blood glucose determination. Blood samples (10 µ L) were collected from the tail vein and mixed with 140 µ L of 0.6 mol/L perchloric acid. After centrifugation, the supernatants were assayed for glucose using an enzymatic assay kit (Glucose CII-test WAKO, Wako Pure Chemicals, Osaka Japan) with the microplate spectrophotometer.
This article has not been copyedited and formatted. The final version may differ from this version. In the study using Zucker fa/fa rats, differences in the AUC values of delta blood glucose between 0 and 3 hr and delta plasma insulin levels at 0.5 hr (that is, the differences between 0 and 0.5 hr) of the vehicle-and ER-319711-treated groups were analyzed using unpaired Student's t-test. Difference of delta plasma active GLP-1 levels at 0.5 hr of the vehicle-and ER-319711-treated groups were determined using
A probability (p) value <0.05 (two-sided) was considered statistically significant.
Statistical analyses were performed using an SAS software package version 8.1 (SAS Institute Japan Ltd., Tokyo, Japan).
This article has not been copyedited and formatted. The final version may differ from this version. human recombinant DPP-IV. As illustrated in Figure 2 , ER-319711-15 showed a competitive inhibition pattern well fitted to the Eadie Hofstee plot.
In the OGTT using Zucker fa/fa rats, administration of ER-319711-15 (1 mg/kg) produced a significant decrease in glucose excursion (Fig. 3A) , resulting in a significant decrease in the AUC values of delta blood glucose (Fig. 3B) . We also determined plasma insulin and active GLP-1 levels. A clear elevation of plasma insulin concentrations was observed 0.5 hr after glucose administration (Fig. 3C ). Delta plasma insulin levels at 0.5 hr were significantly higher in the ER-319711-treated rats than in the vehicle-treated rats (Fig. 3D ). In the same way, a peak of plasma active GLP-1 levels was seen at 0.5 hr in the ER-319711 group, while no peak was detected in the vehicle group (Fig. 3E) . Figure 5F indicates delta plasma active GLP-1 levels at 0.5 hr,
showing a significant increase in active GLP-1 levels by the ER-319711-15 treatment (Fig. 3F ).
We performed an OGTT in which we administered ER-319711-15 (0.1, 0.3, 1, 3 This article has not been copyedited and formatted. The final version may differ from this version. Kinetics study indicated that ER-319711-15 inhibited DPP-IV competitively. In an OGTT using Zucker fa/fa rats, we confirmed that ER-319711-15 improved glucose tolerance, accompanied with increases in both plasma insulin and intact GLP-1 levels.
These are characteristic actions of DPP-IV inhibitors. In addition, ER-319711-15 ameliorated glucose tolerance in mice fed a high-fat diet and this effect was dose-dependent.
A recent focus of research of DPP-IV inhibitors is on long-acting inhibitors, aiming at less dosing frequency. Vildagliptin, which is a slow-binding DPP-IV inhibitor, was dosed to patients with type 2 diabetes once daily, then improving glycemic control (Ristic et al., 2005) . diet, at the same dose of 10 mg/kg. E3024 is a selective and competitive DPP-IV inhibitor with an imidazopyridazinone structure discovered in our laboratories (Yasuda et al., in press) . In an OGTT with a simultaneous administration of the compound and glucose (0 hr), all compounds showed drastic decreases in blood glucose to the same degree. In a 5-hr postdose OGTT, we observed an equal, significant glucose-lowering effect between 10 mg/kg ER-319711-15 and 10 mg/kg vildagliptin. E3024, however, did not manifest significant decrease in AUC values. Thus, ER-319711-15 might be a longer active competitive DPP-IV inhibition than E3024.
DPP-IV is a member of a family of serine peptidases including quiescent cell proline dipeptidase, DPP8 and DPP9. Acute and chronic administration of a DPP-IV inhibitor with DPP8/9 inhibition activity caused thrombocytopenia and splenomegaly in rats, and bloody diarrhea in dogs (Lankas et al., 2005) . A selective DPP8/9 inhibitor caused the same signs, while no toxicity was observed in rats or dogs treated with a selective DPP-IV inhibitor, suggesting that inhibition of DPP8/9 leads to profound toxicity in preclinical studies. Lankas et al. (2005) suggested that preclinical assessment of clinical DPP-IV inhibitor candidates for DPP8/9 inhibition might be important. Our study showed that ER-319711-15 had an inhibitory activity for DPP-IV, but no activity for DPP8 or DPP9 at up to 100 µ mol/L. On the other hand, Lys[Z(NO 2 )] pyrrolidide inhibited not only DPP-IV, but also DPP8 and DPP9 strongly, as reported previously (Lankas et al., 2005) . Accordingly, ER-319711-15 is a specific inhibitor to DPP-IV, and has a low risk of DPP8/9-related toxicity.
In summary, ER-319711-15 is a competitive and selective DPP-IV inhibitor with an 8-oxo-purine structure. Its glucose-lowering effect lasts longer than E3024's. Thus, ER-319711 might be a novel potent DPP-IV inhibitor with an antihyperglycemic activity.
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